CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene editing candidate for blood … – Seeking Alpha
FierceBiotech |
CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene editing candidate for blood …
Seeking Alpha CRISPR Therapeutics (CRSP -4.9%) and Vertex Pharmaceuticals (VRTX -0.5%) have agreed to co-develop and co-commercialize CTX001, a gene editing treatment for β-thalassemia and sickle cell disease (SCD). A Phase 1/2 study in Europe should launch next … Vertex licenses blood disorder gene therapy from CRISPR Therapeutics Growth Insights on the Global CRISPR/Cas9 Tools Market 2017: A Disruptive Technology – Gene-editing Tools for … Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co … |
